<p>英特格拉生命科学最近的财报电话会议呈现出复杂的情绪，反映了运营成功与持续挑战。公司展示了强大的运营效率和战略进展，例如关键产品的提前重新推出。然而，这些积极因素受到供应链中断、耳鼻喉科和私人标签业务的挑战以及下调的全年指引的影响，整体表现呈现出混合的状态。</p>
<h2>强劲的有机收入增长</h2>
<p>尽管面临多重挑战，英特格拉生命科学实现了约 5% 的有机收入同比增长。本季度总收入达到 4.02 亿美元，突显了公司在艰难环境中维持增长的能力。</p>
<h2>调整后的每股收益超出指引</h2>
<p>公司本季度的调整后每股收益为 0.54 美元，超出了指引范围的上限。这一成就反映了强大的运营效率和有效的成本管理，展示了公司优化运营的能力。</p>
<h2>英特格拉皮肤生产显著改善</h2>
<p>英特格拉生命科学报告称，其英特格拉皮肤的生产产量显著提高，增幅超过 50%。此外，自 1 月以来，库存水平增加了 2.5 倍，表明公司在生产和库存管理方面采取了强有力的策略。</p>
<h2>PriMatrix 和 Durepair 的成功重新推出</h2>
<p>PriMatrix 和 Durepair 的提前重新推出，得益于双重采购策略，增强了公司的供应链韧性。这一战略举措使公司能够提前重新引入这些关键产品。</p>
<h2>强劲的国际增长</h2>
<p>英特格拉生命科学的国际收入增长了 14.6%，得益于强劲的需求和产品的重新供应。值得注意的是，中国的同比增长达到了 24%，突显了公司不断扩大的全球足迹。</p>
<h2>收入低于预期</h2>
<p>尽管整体增长，收入因 CSS 业务的两次供应中断和安全库存水平不足而低于预期。这一短缺突显了维持供应链稳定性所面临的持续挑战。</p>
<h2>耳鼻喉科和私人标签业务的挑战</h2>
<p>耳鼻喉科业务保持平稳，受到报销压力和资本设备采购时机的影响。此外，私人标签销售下降了 12.6%，反映出这些领域的挑战。</p>
<h2>MediHoney 面临压力</h2>
<p>由于在合规主计划下进行的持续整改工作，MediHoney 的销售受到影响，显示出该产品线面临的挑战。</p>
<h2>下调全年指引</h2>
<p>英特格拉生命科学将 2025 年全年的收入和调整后每股收益指引修订为 16.2 亿至 16.4 亿美元和 2.19 至 2.24 美元。这一调整反映了公司的混合表现和持续挑战。</p>
<h2>毛利率下降</h2>
<p>本季度的毛利率报告为 62.9%，同比下降 10 个基点。这一下降归因于整改成本和关税的增加，影响了公司的盈利能力。</p>
<h2>前瞻性指引</h2>
<p>展望未来，英特格拉生命科学为 2025 财年提供了更新的指引，预计收入在 16.2 亿至 16.4 亿美元之间，调整后的每股收益范围为 2.19 至 2.24 美元。公司仍然专注于执行其合规主计划，提高运营效率，并保持严格的成本管理。他们预计 2026 年将实现适度的收入增长，得益于战略举措和预计节省 2500 万至 3000 万美元的成本节约措施。</p>
<p>总之，英特格拉生命科学的财报电话会议反映出复杂的情绪，平衡了强大的运营效率和战略进展与供应链和特定业务领域的持续挑战。尽管面临这些障碍，公司对未来的增长仍持乐观态度，得益于战略举措和成本节约措施。</p>

英特格拉生命科学

<p>英特格拉生命科学最近的财报电话会议显示出混合的情绪，展示了运营成功与挑战并存。公司报告了 5% 的有机收入增长，总收入为 4.02 亿美元，调整后的每股收益为 0.54 美元，超出预期。然而，供应链中断以及耳鼻喉科和私人标签业务的挑战导致全年指导下调至 16.2 亿至 16.4 亿美元。尽管毛利率下降至 62.9%，公司预计到 2026 年将实现适度增长，这得益于战略举措和节省成本的措施</p>

<p>The recent earnings call for Integra LifeSciences presented a mixed sentiment, reflecting both operational successes and ongoing challenges. The company showcased strong operational efficiency and strategic advancements, such as the early relaunch of key products. However, these positives were tempered by supply chain disruptions, challenges in the ENT and Private Label segments, and a lowered full-year guidance, indicating a mixed performance overall.</p>
<div class="lb-trans"><p>英特格拉生命科学最近的财报电话会议呈现出复杂的情绪，反映了运营成功与持续挑战。公司展示了强大的运营效率和战略进展，例如关键产品的提前重新推出。然而，这些积极因素受到供应链中断、耳鼻喉科和私人标签业务的挑战以及下调的全年指引的影响，整体表现呈现出混合的状态。</p>
</div><h2>Strong Organic Revenue Growth</h2>
<div class="lb-trans"><h2>强劲的有机收入增长</h2>
</div><p>Despite facing several challenges, Integra LifeSciences achieved an impressive organic revenue growth of approximately 5% year-over-year. The total revenues for the quarter reached $402 million, highlighting the company’s ability to sustain growth even in a challenging environment.</p>
<div class="lb-trans"><p>尽管面临多重挑战，英特格拉生命科学实现了约 5% 的有机收入同比增长。本季度总收入达到 4.02 亿美元，突显了公司在艰难环境中维持增长的能力。</p>
</div><h2>Adjusted EPS Exceeds Guidance</h2>
<div class="lb-trans"><h2>调整后的每股收益超出指引</h2>
</div><p>The company’s adjusted EPS for the quarter was $0.54, surpassing the top end of the guidance range. This achievement reflects strong operational efficiency and effective cost management, showcasing the company’s ability to optimize its operations.</p>
<div class="lb-trans"><p>公司本季度的调整后每股收益为 0.54 美元，超出了指引范围的上限。这一成就反映了强大的运营效率和有效的成本管理，展示了公司优化运营的能力。</p>
</div><h2>Significant Improvement in Integra Skin Production</h2>
<div class="lb-trans"><h2>英特格拉皮肤生产显著改善</h2>
</div><p>Integra LifeSciences reported a significant improvement in its Integra Skin manufacturing yields, which increased by more than 50%. Additionally, inventory levels have increased by 2.5 times since January, indicating a robust production and inventory management strategy.</p>
<div class="lb-trans"><p>英特格拉生命科学报告称，其英特格拉皮肤的生产产量显著提高，增幅超过 50%。此外，自 1 月以来，库存水平增加了 2.5 倍，表明公司在生产和库存管理方面采取了强有力的策略。</p>
</div><h2>Successful Relaunch of PriMatrix and Durepair</h2>
<div class="lb-trans"><h2>PriMatrix 和 Durepair 的成功重新推出</h2>
</div><p>The early relaunch of PriMatrix and Durepair, facilitated by a dual sourcing strategy, has improved the company’s supply chain resilience. This strategic move allowed the company to reintroduce these key products ahead of schedule.</p>
<div class="lb-trans"><p>PriMatrix 和 Durepair 的提前重新推出，得益于双重采购策略，增强了公司的供应链韧性。这一战略举措使公司能够提前重新引入这些关键产品。</p>
</div><h2>Strong International Growth</h2>
<div class="lb-trans"><h2>强劲的国际增长</h2>
</div><p>International revenue for Integra LifeSciences grew by 14.6%, driven by strong demand and renewed product availability. Notably, China showed a remarkable 24% year-over-year increase, underscoring the company’s expanding global footprint.</p>
<div class="lb-trans"><p>英特格拉生命科学的国际收入增长了 14.6%，得益于强劲的需求和产品的重新供应。值得注意的是，中国的同比增长达到了 24%，突显了公司不断扩大的全球足迹。</p>
</div><h2>Revenue Below Expectations</h2>
<div class="lb-trans"><h2>收入低于预期</h2>
</div><p>Despite the overall growth, revenue fell below expectations due to two supply interruptions in the CSS business and insufficient safety stock levels. This shortfall highlights the ongoing challenges in maintaining supply chain stability.</p>
<div class="lb-trans"><p>尽管整体增长，收入因 CSS 业务的两次供应中断和安全库存水平不足而低于预期。这一短缺突显了维持供应链稳定性所面临的持续挑战。</p>
</div><h2>Challenges in ENT and Private Label Business</h2>
<div class="lb-trans"><h2>耳鼻喉科和私人标签业务的挑战</h2>
</div><p>The ENT business remained flat, affected by reimbursement pressures and the timing of capital equipment purchases. Additionally, Private Label sales saw a decline of 12.6%, reflecting challenges in these segments.</p>
<div class="lb-trans"><p>耳鼻喉科业务保持平稳，受到报销压力和资本设备采购时机的影响。此外，私人标签销售下降了 12.6%，反映出这些领域的挑战。</p>
</div><h2>MediHoney Under Pressure</h2>
<div class="lb-trans"><h2>MediHoney 面临压力</h2>
</div><p>Sales of MediHoney were impacted due to ongoing remediation efforts under the Compliance Master Plan, indicating the challenges faced in this product line.</p>
<div class="lb-trans"><p>由于在合规主计划下进行的持续整改工作，MediHoney 的销售受到影响，显示出该产品线面临的挑战。</p>
</div><h2>Lowered Full Year Guidance</h2>
<div class="lb-trans"><h2>下调全年指引</h2>
</div><p>Integra LifeSciences revised its full-year 2025 revenue and adjusted EPS guidance to $1.62 billion to $1.64 billion and $2.19 to $2.24, respectively. This adjustment reflects the mixed performance and ongoing challenges faced by the company.</p>
<div class="lb-trans"><p>英特格拉生命科学将 2025 年全年的收入和调整后每股收益指引修订为 16.2 亿至 16.4 亿美元和 2.19 至 2.24 美元。这一调整反映了公司的混合表现和持续挑战。</p>
</div><h2>Gross Margin Decline</h2>
<div class="lb-trans"><h2>毛利率下降</h2>
</div><p>The gross margin for the quarter was reported at 62.9%, a decline of 10 basis points year-over-year. This decrease was attributed to increased remediation costs and tariffs, impacting the company’s profitability.</p>
<div class="lb-trans"><p>本季度的毛利率报告为 62.9%，同比下降 10 个基点。这一下降归因于整改成本和关税的增加，影响了公司的盈利能力。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指引</h2>
</div><p>Looking ahead, Integra LifeSciences has provided updated guidance for the fiscal year 2025, with projected revenue between $1.62 billion and $1.64 billion, and an adjusted EPS range of $2.19 to $2.24. The company remains focused on executing its Compliance Master Plan, improving operational efficiency, and maintaining disciplined cost management. They anticipate modest revenue growth in 2026, supported by strategic initiatives and cost-saving measures expected to yield $25 million to $30 million in savings.</p>
<div class="lb-trans"><p>展望未来，英特格拉生命科学为 2025 财年提供了更新的指引，预计收入在 16.2 亿至 16.4 亿美元之间，调整后的每股收益范围为 2.19 至 2.24 美元。公司仍然专注于执行其合规主计划，提高运营效率，并保持严格的成本管理。他们预计 2026 年将实现适度的收入增长，得益于战略举措和预计节省 2500 万至 3000 万美元的成本节约措施。</p>
</div><p>In summary, the earnings call for Integra LifeSciences reflected a mixed sentiment, balancing strong operational efficiencies and strategic advancements with ongoing challenges in supply chain and specific business segments. Despite these hurdles, the company remains optimistic about its future growth, supported by strategic initiatives and cost-saving measures.</p>
<div class="lb-trans"><p>总之，英特格拉生命科学的财报电话会议反映出复杂的情绪，平衡了强大的运营效率和战略进展与供应链和特定业务领域的持续挑战。尽管面临这些障碍，公司对未来的增长仍持乐观态度，得益于战略举措和成本节约措施。</p>
</div>

英特格拉生命科学财报电话会议：情绪复杂与战略进展